相关实验视频

Updated: Jul 5, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

伊朗的多抗药结核病:一个多中心研究

Fatemeh Khelghati¹, Fatemeh Nasirpour Seilakhori¹, Mehdi Goudarzi¹

¹Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

|January 12, 2024

概括

抗药性结核病 (MDR-TB) 是一个日益严重的全球性问题. 伊朗的一项研究发现,在肺结核患者中,MDR-TB的患病率低至0.6%,这凸显了改善诊断和治疗策略的必要性.

科学领域:

医学微生物学医学微生物学
传染性疾病传染性疾病
公共卫生公共卫生

背景情况:

耐多药结核病 (MDR-TB) 是一个重大的全球卫生挑战.
伊朗面临着日益增长的MDR-TB发病率,但目前对肺结核患者患病率的研究有限.
有效的控制策略需要最新的药物耐药性模式数据.

研究的目的:

确定伊朗肺结核患者中MDR-TB的流行率.
确定导致该国结核病和MDR-TB病例增加的潜在因素.
为改善治疗和诊断方法的发展提供信息.

主要方法:

一项涉及伊朗五个地区结核病实验室1216个呼吸道样本的横截面研究.
使用基于IS6110的PCR和Xpert MTB/RIF测定来识别Mycobacterium结核病.
使用常规比例方法进行的药物敏感性测试 (DST).

主要成果:

在448个阳性M.结核病单体中,445个 (99.4%) 对测试药物敏感.
只有3个孤立 (0.6%) 被确定为多药耐药 (MDR).
该研究确立了伊朗受研究人口当前的MDR-TB患病率为0.6%.

结论:

伊朗的MDR-TB的流行率目前很低,为0.6%.
针对DST的实验室基础设施不足和缺乏最新的治疗方案可能会导致MDR-TB的潜在增加.
加强治疗管理和采用新技术对于打击伊朗的结核病和MDR-TB至关重要.

更多相关视频

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: